|
Dr.Tollefson was appointed to the Board of Directors in March 2004. A Distinguished Visiting Lilly Research Scholar and Clinical Professor of Psychiatry at the Indiana University School of Medicine, he brings to Cortex’s Board vast experience in neuroscience and significant business accomplishments at Eli Lilly & Company, playing a key strategic role in its blockbuster antidepressant and antipsychotic drugs Prozac® and Zyprexia®, respectively. Dr. Tollefson’s career highlights include having served as Distinguished Lilly Research Scholar and Vice President Medical-Neuroscience; President, Neuroscience Products and Vice President, Lilly Research Laboratories.He joined Eli Lilly & Company in June 1991 as an Executive Director of Lilly Research Laboratories with responsibility for Prozac®. He then assumed responsibility for the global medical planning of CNS drug development from Phase I through post marketing studies. Dr. Tollefson has also been actively involved with the FDA’s Neuropsychopharmacology Division with Lilly’s CNS products including: Cymbalta®, a new antidepressant; Symbiax®, a new treatment for bipolar depression; Zyprexa®, the top selling antipsychotic; Strattera®, a new treatment for Attention Deficit Hyperactivity Disorder; and multiple product-line extensions. Dr. Tollefson was Chairman of the Department of Psychiatry, St. Ramsey Medical Center, a University of Minnesota Teaching Affiliate Hospital. He received his B.S (Psychology), M.D. and Ph.D. (Psychopharmacology) from the University of Minnesota. Dr. Tollefson has authored or co-authored over 190 peer-reviewed scientific publications and been awarded 22 method of treatment patents. | 